- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06072183
104-tygodniowe badanie stosowania rytlecitynibu w kapsułkach doustnych u dorosłych z niesegmentowym bielactwem nabytym (aktywnym i stabilnym) Tranquillo 2 (Tranquillo 2)
Randomizowane, podwójnie zaślepione, 52-tygodniowe wieloośrodkowe badanie fazy 3 z podwójnie ślepą próbą, kontrolowane placebo, z 52-tygodniowym okresem przedłużenia z podwójnie ślepą próbą i randomizowanym zwiększaniem/zmniejszaniem dawki, badanie skuteczności, bezpieczeństwa i tolerancji rytlecitynibu u dorosłych uczestników Z bielactwem niesegmentowym
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sides of the body such as both knees and both hands.
Ritlecitinib has been tested in earlier clinical studies and has a favorable safety profile. At present there are no approved medications taken by mouth to treat nonsegmental vitiligo.
This study is seeking participants who:
- Are 18 years of age or older.
- are confirmed to have nonsegmental vitiligo for at least 3 months.
- Are willing to stop all other treatments that they may be taking for vitiligo.
In this study participants will be chosen by chance, like drawing names out of a hat to receive 1 of 3 treatments:
•Part I where two different amounts of ritlecitinib (50 mg and 100 mg) are taken once daily. It will be compared to placebo. Placebo is a dummy capsule. It doesn't have any medicine used in the study.
Participants receiving placebo who have not responded to treatment after 52 weeks will be given 100 milligrams or 50 milligrams of ritlecitinib for the remaining 52 weeks of the study.
• In Part II, participants will only receive 100 milligrams of ritlecitinib. About 1000 participants will take part in Part I and around 450 in Part II globally. The study will compare the experiences of people receiving ritlecitinib to those of the people who do not. This will help see if ritlecitinib is safe and effective.
People in Part I will be in this study for about 26 months and people in Part II will be in this study for about 14 months. During the study, participants in part I will need to visit the study site at least 17 times. In part II, participants will visit at least 11 times.
Participants will undergo various tests and procedures such as:
- vitiligo rating,
- physical examinations,
- hearing tests,
- blood tests,
- x-ray,
- ECG,
- photographs of areas with vitiligo. Participants will be asked to complete questionnaires about their vitiligo.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Study B7981080 is a Phase 3 randomized, double-blind, multicenter study with a 52-week placebo-controlled period (Part Ia) followed by a double-blind 52-week extension period (Part Ib) that includes randomized dose-up/down titration and a de novo 52-week non-randomized open-label cohort (Part II), investigating the efficacy, safety, and tolerability of ritlecitinib 100 mg QD and 50 mg QD compared with placebo in adult participants with nonsegmental active or stable vitiligo
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Australian Capital Territory
-
Phillip, Australian Capital Territory, Australia, 2606
- Paratus Clinical Research Woden
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- St George Dermatology & Skin Cancer Centre
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
-
Queensland
-
Greenslopes, Queensland, Australia, 4120
- Veracity Clinical Research
-
-
South Australia
-
Campbelltown, South Australia, Australia, 5074
- North Eastern Health Specialists
-
Woodville South, South Australia, Australia, 5011
- The Queen Elizabeth Hospital
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Dr Rodney Sinclair Pty Ltd
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
Mitcham, Victoria, Australia, 3132
- Institute for Skin, Health and Immunity
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital
-
-
Western Australia
-
Fremantle, Western Australia, Australia, 6160
- Fremantle Dermatology
-
-
-
-
Bruxelles-capitale, Région de
-
Brussels, Bruxelles-capitale, Région de, Belgia, 1070
- Université Libre de Bruxelles - Hôpital Erasme
-
Brussels, Bruxelles-capitale, Région de, Belgia, 1200
- Cliniques universitaires Saint-Luc
-
-
LIÈGE
-
Liège, LIÈGE, Belgia, 4000
- Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
-
-
OOST-VLAANDEREN
-
Ghent, OOST-VLAANDEREN, Belgia, 9000
- UZ Gent
-
-
VLAAMS-BRABANT
-
Leuven, VLAAMS-BRABANT, Belgia, 3000
- UZ Leuven
-
-
-
-
-
Sofia, Bułgaria, 1202
- Diagnostic Consultative Center "Ascendent"
-
-
Pazardzhik
-
Pazardzhik, Pazardzhik, Bułgaria, 4400
- MHAT Pazardzhik
-
-
Pernik
-
Pernik, Pernik, Bułgaria, 2300
- Diagnostic Consultative Center 1 - Pernik
-
-
Pleven
-
Pleven, Pleven, Bułgaria, 5800
- Medical Center Exacta Medica
-
-
Ruse
-
Rousse, Ruse, Bułgaria, 7000
- Medical Center Prolet EOOD
-
-
Sofia
-
Sofia, Sofia, Bułgaria, 1528
- Diagnostic - Consultative Center XXVIII - Sofia
-
Sofia, Sofia, Bułgaria, 1618
- "Diagnostic - Consultative Center XX - Sofia" EOOD
-
-
Sofia (stolitsa)
-
Sofia, Sofia (stolitsa), Bułgaria, 1431
- Diagnostic Consultative Center Aleksandrovska
-
Sofia, Sofia (stolitsa), Bułgaria, 1407
- ASMC - IPSMC - skin and venereal diseases
-
Sofia, Sofia (stolitsa), Bułgaria, 1463
- Diagnostic Consultative Centre (DCC) - Foкus 5
-
Sofia, Sofia (stolitsa), Bułgaria, 1606
- Clinic EvroDerma
-
-
Stara Zagora
-
Stara Zagora, Stara Zagora, Bułgaria, 6003
- UMHAT "Prof. Dr. Stoyan Kirkovich"AD
-
-
Veliko Tarnovo
-
Veliko Tarnovo, Veliko Tarnovo, Bułgaria, 5000
- Center for Skin and Venereal Diseases - Veliko Tarnovo
-
-
Yambol
-
Yambol, Yambol, Bułgaria, 8600
- Multiprofile Hospital for Active Treatment Sv. Panteleymon - Yambol AD
-
-
-
-
-
Shanghai, Chiny, 200080
- Shanghai General Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chiny, 100730
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, Chiny, 100050
- Beijing Friendship Hospital Affiliate of Capital University
-
-
Fujian
-
Fuzhou, Fujian, Chiny, 350005
- The First Affiliated Hospital Of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Chiny, 510180
- Guangzhou First People's Hospital
-
Guangzhou, Guangdong, Chiny, 510091
- Dermatology Hospital of Southern Medical University
-
-
Guizhou
-
Guiyang, Guizhou, Chiny, 550004
- The Affiliated Hospital of Guizhou Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, Chiny, 050030
- The First Hospital of Hebei Medical University
-
-
Henan
-
Nanyang, Henan, Chiny, 473000
- NanYang First people's hospital
-
-
Hubei
-
Wuhan, Hubei, Chiny, 430022
- The First Hospital of Wuhan
-
-
Hunan
-
Changsha, Hunan, Chiny, 410011
- The Second Xiangya Hospital of Central South University
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, Chiny, 014010
- The First Affiliated Hospital of Baotou Medical College
-
-
Jiangsu
-
Nanjing, Jiangsu, Chiny, 210029
- Jiangsu Province Hospital
-
-
Jilin
-
Changchun, Jilin, Chiny, 130021
- The First Hospital of Jilin University
-
-
Shaanxi
-
Xi'an, Shaanxi, Chiny, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 200040
- Huashan Hospital, Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, Chiny, 610041
- West China Hospital, Sichuan University
-
Chengdu, Sichuan, Chiny, 610017
- Chengdu second people's hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chiny, 300052
- Tianjin Medical University General Hospital
-
-
Yunnan
-
Kunming, Yunnan, Chiny, 650032
- First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chiny, 310009
- Hangzhou Third Hospital
-
Hangzhou, Zhejiang, Chiny, 310016
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
-
-
-
-
-
Santiago de Compostela, Hiszpania, 15702
- Clínica Gaias - Santiago
-
-
Andalusia
-
Córdoba, Andalusia, Hiszpania, 14004
- Hospital Universitario Reina Sofia
-
Córdoba, Andalusia, Hiszpania, 14001
- AUDIKA
-
-
BARCELONA
-
Barcelona, BARCELONA, Hiszpania, 08041
- Hospital de la Santa Creu i Sant Pau
-
-
Barcelona [barcelona]
-
Badalona, Barcelona [barcelona], Hiszpania, 08916
- Hospital Germans Trias i Pujol
-
L'Hospitalet de Llobregat, Barcelona [barcelona], Hiszpania, 08907
- Hospital Universitari de Bellvitge
-
-
Galicia [galicia]
-
Santiago de Compostela, Galicia [galicia], Hiszpania, 15702
- Clínica Gaias - Santiago
-
-
Madrid
-
Madrid, Madrid, Hiszpania, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Madrid, Hiszpania, 28027
- Clinica Universidad de Navarra
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Hiszpania, 28031
- Hospital Universitario Infanta Leonor
-
-
VALÈNCIA
-
Valencia, VALÈNCIA, Hiszpania, 46026
- Hospital Universitari i Politecnic La Fe
-
-
ZARAGOZA
-
Zaragoza, ZARAGOZA, Hiszpania, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japonia, 457-8510
- Japan Community Health Care Organization Chukyo Hospital
-
-
Chiba
-
Sakura, Chiba, Japonia, 285-8741
- Toho University Sakura Medical Center
-
Urayasu, Chiba, Japonia, 279-0021
- Juntendo University Urayasu Hospital
-
-
Hyōgo
-
Takarazuka, Hyōgo, Japonia, 665-0827
- Takarazuka City Hospital
-
-
Ibaraki
-
Inashiki-gun, Ibaraki, Japonia, 300-0395
- Tokyo Medical University Ibaraki Medical Center
-
-
Nara
-
Ikoma, Nara, Japonia, 630-0293
- Kindai University Nara Hospital
-
-
Osaka
-
Habikino, Osaka, Japonia, 583-8588
- Osaka Habikino Medical Center
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japonia, 431-3192
- Hamamatsu University Hospital
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japonia, 113-8519
- Institute of Science Tokyo Hospital
-
-
Yamaguchi
-
Ube, Yamaguchi, Japonia, 755-8505
- Yamaguchi University Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2J 7E1
- Dermatology Research Institute
-
Edmonton, Alberta, Kanada, T6G 1C3
- Alberta Dermasurgery Centre
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E8
- The Skin Care Centre
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3M 3Z4
- Wiseman Dermatology Research Inc.
-
-
Ontario
-
Barrie, Ontario, Kanada, L4M 7G1
- SimcoDerm Medical and Surgical Dermatology Center
-
Greater Sudbury, Ontario, Kanada, P3C 1X3
- Medicor Research Inc
-
Greater Sudbury, Ontario, Kanada, P3C 1X8
- Sudbury Skin Clinique
-
London, Ontario, Kanada, N6H 5L5
- DermEffects
-
Mississauga, Ontario, Kanada, L4Y 4C5
- DermEdge Research
-
Oakville, Ontario, Kanada, L6J 7W5
- The Centre for Clinical Trials
-
Ottawa, Ontario, Kanada, K1K 4L2
- JRB Research Inc.
-
Richmond Hill, Ontario, Kanada, L4B 1L1
- York Dermatology Clinic & Research Centre
-
Toronto, Ontario, Kanada, M2N 3A6
- North York Research Inc
-
Toronto, Ontario, Kanada, M4W 2N4
- Dermatology on Bloor - Research Toronto
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 2V1
- Innovaderm Research Inc.
-
Montreal, Quebec, Kanada, H1Y 3L1
- Centre de Recherche Saint-Louis (Montréal)
-
Québec, Quebec, Kanada, G2J 0C4
- Alpha Recherche Clinique
-
Québec, Quebec, Kanada, G1V 4X7
- Centre de Recherche Dermatologique du Quebec metropolitain
-
Québec, Quebec, Kanada, G1V 4T3
- Diex Recherche Quebec
-
Sherbrooke, Quebec, Kanada, J1L 0H8
- Diex Recherche Sherbrooke
-
Sherbrooke, Quebec, Kanada, J1G 1X9
- Centre de Recherche Saint-Louis
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7K 2C1
- Skinsense Medical Research
-
Saskatoon, Saskatchewan, Kanada, S7T 0G3
- Saskatoon Dermatology Centre
-
-
-
-
Chihuahua
-
Chihuahua City, Chihuahua, Meksyk, 31238
- Servicios Hospitalarios de Mexico S.A. DE C.V.
-
-
Mexico City
-
Mexico City, Mexico City, Meksyk, 06700
- Trials in Medicine
-
-
Michoacán
-
Morelia, Michoacán, Meksyk, 58249
- Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC
-
-
Nuevo León
-
Monterrey, Nuevo León, Meksyk, 64060
- Cri Centro Regiomontano de Investigacion
-
-
Veracruz
-
Veracruz, Veracruz, Meksyk, 91900
- Arké SMO S.A de C.V
-
-
-
-
-
Dresden, Niemcy, 01307
- Universitaetsklinikum Carl Gustav Carus Dresden
-
-
Hesse
-
Darmstadt, Hesse, Niemcy, 64283
- Rosenpark Research GmbH
-
-
North Rhine-Westphalia
-
Bielefeld, North Rhine-Westphalia, Niemcy, 33647
- Klinikum Bielefeld Rosenhöhe
-
Bielefeld, North Rhine-Westphalia, Niemcy, 33647
- Klinikum Bielefeld gem. GmbH
-
Bochum, North Rhine-Westphalia, Niemcy, 44793
- Hautzentrum im Jahrhunderthaus
-
Bonn, North Rhine-Westphalia, Niemcy, 53127
- Universitätsklinikum Bonn
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Niemcy, 55128
- BAG Drs. Med. Quist PartG
-
-
Saxony
-
Dresden, Saxony, Niemcy, 01097
- Hautarztpraxis Dr. Beatrice Gerlach
-
Leipzig, Saxony, Niemcy, 04207
- Hautarztpraxis Dr. Neubauer
-
-
Saxony-Anhalt
-
Magdeburg, Saxony-Anhalt, Niemcy, 39104
- HNO-Praxis Dr. Kugler in Magdeburg
-
Magdeburg, Saxony-Anhalt, Niemcy, 39104
- Magdeburger Company for Medical Studies and Services
-
Magdeburg, Saxony-Anhalt, Niemcy, 39104
- Radiologie Ulrichshaus
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polska, 85-650
- Clinica Dermatoestetica Prywatny Gabinet Dermatologiczny I Alergologiczny Prof.Dr Hab.Med. Barbara Z
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polska, 30-002
- Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka
-
Krakow, Lesser Poland Voivodeship, Polska, 31-501
- Krakowskie Centrum Medyczne
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polska, 02-677
- ETG Warszawa
-
Warsaw, Masovian Voivodeship, Polska, 02-953
- Klinika Ambroziak Dermatologia
-
Warsaw, Masovian Voivodeship, Polska, 02-962
- Royalderm Agnieszka Nawrocka
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polska, 15-375
- Specderm Poznanska sp.j.
-
Bialystok, Podlaskie Voivodeship, Polska, 15-879
- ClinicMed Daniluk, Nowak Spółka komandytowa
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polska, 40-611
- Centrum Medyczne Angelius Provita
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Polska, 71-500
- Twoja Przychodnia SCM
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polska, 90-265
- "DERMED" Centrum Medyczne Sp. z o.o.
-
-
-
-
-
San Juan, Portoryko, 00909
- Clinical Research Puerto Rico
-
San Juan, Portoryko, 00909
- Cardiovascular Radiology Institute
-
San Juan, Portoryko, 00927
- Centro de Audiología y Balance
-
-
-
-
Arizona
-
Scottsdale, Arizona, Stany Zjednoczone, 85260
- Center for Dermatology and Plastic Surgery/CCT Research
-
-
Arkansas
-
Bryant, Arkansas, Stany Zjednoczone, 72022
- Dermatology Trial Associates
-
-
California
-
Fountain Valley, California, Stany Zjednoczone, 92708
- First OC Dermatology Research Inc
-
Huntington Beach, California, Stany Zjednoczone, 92648
- Seaside Audiology Vertigo & Ear Specialists
-
Los Angeles, California, Stany Zjednoczone, 90056
- Wallace Medical Group, Inc
-
Oakland, California, Stany Zjednoczone, 94611
- Kaiser Permanente
-
Oxnard, California, Stany Zjednoczone, 93030
- Cura Clinical Research - Oxnard
-
Rancho Santa Margarita, California, Stany Zjednoczone, 92688
- Mission Dermatology Center
-
Rolling Hills Estates, California, Stany Zjednoczone, 90274
- Peninsula Research Associates
-
Sacramento, California, Stany Zjednoczone, 95815
- Integrative Skin Science and Research
-
San Diego, California, Stany Zjednoczone, 92122
- University of California San Diego - La Jolla
-
Santa Ana, California, Stany Zjednoczone, 92706
- Wolverine Clinical Trials
-
-
Florida
-
Boynton Beach, Florida, Stany Zjednoczone, 33436
- Encore Medical Research of Boynton Beach
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33308
- FXM Clinical Research - Fort Lauderdale
-
Hialeah, Florida, Stany Zjednoczone, 33012
- Direct Helpers Research Center
-
Miami, Florida, Stany Zjednoczone, 33136
- University of Miami
-
Miami, Florida, Stany Zjednoczone, 33165
- New Horizon Research Center
-
Miami, Florida, Stany Zjednoczone, 33136
- SouthCoast Research Center
-
Miami, Florida, Stany Zjednoczone, 33173
- Well Pharma Medical Research, Corp.
-
Miami, Florida, Stany Zjednoczone, 33173
- Skin Research of South Florida
-
Miami, Florida, Stany Zjednoczone, 33144
- Bio-Medical Research LLC
-
Miami, Florida, Stany Zjednoczone, 33126
- Clever Medical Research
-
Miami, Florida, Stany Zjednoczone, 33133
- Miami Dermatology and Laser Research
-
Miami, Florida, Stany Zjednoczone, 33175
- FXM Clinical Research - Miami
-
Miami, Florida, Stany Zjednoczone, 33176
- Health and Life Research Institute
-
Miami, Florida, Stany Zjednoczone, 33176
- University of Miami, Kendall Office
-
Miami, Florida, Stany Zjednoczone, 33179
- Floridian Research Institute Llc
-
Miami, Florida, Stany Zjednoczone, 33186
- Sanitas Research
-
Miami, Florida, Stany Zjednoczone, 33136
- University of Miami Dermatology Clinical Trials Unit
-
Miami Lakes, Florida, Stany Zjednoczone, 33016
- Wellness Clinical Research, LLC
-
Miramar, Florida, Stany Zjednoczone, 33027
- FXM Clinical Research Miramar, LLC
-
St. Petersburg, Florida, Stany Zjednoczone, 33714
- GCP Research, Global Clinical professionals
-
Tampa, Florida, Stany Zjednoczone, 33607
- Advanced Clinical Research Institute
-
Tampa, Florida, Stany Zjednoczone, 33612
- USF Health
-
-
Georgia
-
Savannah, Georgia, Stany Zjednoczone, 31419
- Sidney P. Smith, MD, PC dba Georgia Skin & Cancer Clinic
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60625
- Endeavor Health Audiology -CHICAGO
-
Lake Bluff, Illinois, Stany Zjednoczone, 60044
- Endeavor Health Audiology -LAKE BLUFF
-
Northbrook, Illinois, Stany Zjednoczone, 60062
- Endeavor Health Audiology-NORTHBROOK
-
Skokie, Illinois, Stany Zjednoczone, 60076
- Endeavor Health Audiology-SKOKIE
-
Skokie, Illinois, Stany Zjednoczone, 60077
- Endeavor Health-Dermatology Clinical Trials Unit
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46250
- Dawes Fretzin Clinical Research Group, LLC
-
South Bend, Indiana, Stany Zjednoczone, 46617
- The South Bend Clinic, LLC
-
-
Maryland
-
Rockville, Maryland, Stany Zjednoczone, 20850
- Dermatology and Skin Cancer Specialists, LLC
-
-
Michigan
-
Auburn Hills, Michigan, Stany Zjednoczone, 48326
- Oakland Hills Dermatology
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Henry Ford Medical Center - New Center One
-
Detroit, Michigan, Stany Zjednoczone, 48201
- Wayne Health
-
Detroit, Michigan, Stany Zjednoczone, 48201
- CS Mott Center
-
-
Missouri
-
Saint Joseph, Missouri, Stany Zjednoczone, 64506
- MediSearch Clinical Trials
-
-
Nebraska
-
Lincoln, Nebraska, Stany Zjednoczone, 68516
- Physician Research Collaboration, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Stany Zjednoczone, 87102
- University of New Mexico Health Sciences Center
-
-
New York
-
New York, New York, Stany Zjednoczone, 10128
- OptiSkin Medical
-
Stony Brook, New York, Stany Zjednoczone, 11790
- DermResearchCenter of New York, Inc.
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28277
- Darst Dermatology
-
Charlotte, North Carolina, Stany Zjednoczone, 28211
- DJL Clinical Research, PLLC
-
-
Ohio
-
Bexley, Ohio, Stany Zjednoczone, 43209
- Bexley Dermatology Research
-
Columbus, Ohio, Stany Zjednoczone, 43213
- Centricity Research Columbus Ohio Multispecialty
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97210
- Oregon Dermatology and Research Center
-
-
Pennsylvania
-
Plymouth Meeting, Pennsylvania, Stany Zjednoczone, 19462
- Dermatology Associates of Plymouth Meeting
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Stany Zjednoczone, 29212
- Columbia Dermatology & Aesthetics
-
Greenville, South Carolina, Stany Zjednoczone, 29615
- Palmetto Clinical Trial Services, LLC
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77004
- Center for Clinical Studies
-
Pflugerville, Texas, Stany Zjednoczone, 78660
- Austin Institute for Clinical Research
-
Sugar Land, Texas, Stany Zjednoczone, 77479
- Complete Dermatology
-
The Woodlands, Texas, Stany Zjednoczone, 77380
- The Woodlands Dermatology Associates, PA
-
-
Utah
-
Murray, Utah, Stany Zjednoczone, 84107
- University of Utah
-
Springville, Utah, Stany Zjednoczone, 84663
- Springville Dermatology - Springville/CCT Research
-
-
Virginia
-
Forest, Virginia, Stany Zjednoczone, 24551
- Eurofins Cosmetics CRL LLC
-
-
-
-
-
Bratislava, Słowacja, 851 01
- Derma therapy spol. s.r.o.
-
Bratislava, Słowacja, 841 02
- BeneDerma
-
Bratislava, Słowacja, 811 09
- CLINIQ s.r.o.
-
Košice, Słowacja, 040 23
- Poliklinika ProCare Kosice s.r.o.
-
Košice, Słowacja, 04001
- Topskin pro s.r.o.
-
-
Banská Bystrica Region
-
Banská Bystrica, Banská Bystrica Region, Słowacja, 97517
- Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica
-
-
Presov
-
Svidník, Presov, Słowacja, 089 01
- SANARE, s.r.o
-
-
Trnava Region
-
Trnava, Trnava Region, Słowacja, 917 02
- Fakultna nemocnica Trnava
-
-
-
-
-
Kaohsiung City, Tajwan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Kaohsiung City, Tajwan, 833401
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Tajwan, 100225
- National Taiwan University Hospital
-
-
TAOYUAN
-
Taoyuan, TAOYUAN, Tajwan, 333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Taipei
-
Taipei, Taipei, Tajwan, 11217
- Taipei Veterans General Hospital
-
-
-
-
Ankara
-
Ankara, Ankara, Turcja (Türkiye), 06560
- Gazi University Health Research and Application Center Gazi Hospital
-
-
Istanbul
-
Istanbul, Istanbul, Turcja (Türkiye), 34093
- Bezmialem Vakf Üniversitesi
-
-
-
-
-
Debrecen, Węgry, 4031
- DERMA-B Egészségügyi és Szolgáltató
-
Kaposvár, Węgry, 7400
- Derm-Surg Egészségügyi Szolgáltató és Tanácsadó Kft.
-
-
Baranya
-
Pécs, Baranya, Węgry, 7632
- Pécsi Tudományegyetem Klinikai Központ
-
-
Budapest
-
Budapest, Budapest, Węgry, 1036
- Óbudai Egészségügyi Centrum
-
-
Békéscsaba
-
Békéscsaba, Békéscsaba, Węgry, 5600
- Trial Pharma - Semper Medical Center
-
-
Csongrád megye
-
Szeged, Csongrád megye, Węgry, 6720
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
-
-
Debrecen
-
Debrecen, Debrecen, Węgry, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Debrecen, Debrecen, Węgry, 4027
- Orvostudomanyi Kutato es Fejleszto Kft
-
-
-
-
Abruzzo
-
L’Aquila, Abruzzo, Włochy, 67100
- ASL1 Avezzano-Sulmona-L'Aquila
-
-
CAGLIARI
-
Cagliari, CAGLIARI, Włochy, 09124
- Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari
-
-
FIRENZE
-
Florence, FIRENZE, Włochy, 50125
- Presidio Ospedaliero Firenze Centro Piero Palagi
-
-
Lombardy
-
Milan, Lombardy, Włochy, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
-
RM
-
Roma, RM, Włochy, 00144
- IRCCS Istituti Fisioterapici Ospitalieri
-
-
ROMA
-
Rome, ROMA, Włochy, 00148
- Ospedale Israelitico
-
Rome, ROMA, Włochy, 00167
- Istituto Dermopatico Immacolata
-
-
-
-
England
-
Isleworth, England, Zjednoczone Królestwo, TW7 6AF
- West Middlesex University Hospital
-
-
HAMPSHIRE
-
Southampton, HAMPSHIRE, Zjednoczone Królestwo, SO16 6YD
- Southampton General Hospital
-
-
London, CITY of
-
London, London, CITY of, Zjednoczone Królestwo, SE1 9RT
- Guy's & St Thomas' NHS Foundation Trust
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Participants aged 18 years (or the minimum age of consent in accordance with local regulations) or older (no upper age limit) at Screening.
• Meeting reproductive criteria for female participants.
Disease Characteristics:
-
Eligible participants must have at both Screening and BL:
- A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and
- BSA involvement 4% to 60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet and
- BSA ≥0.5% involvement on the face. Face is defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. Face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and
- F-VASI ≥0.5 and T-VASI ≥3; and
- Either active or stable nonsegmental vitiligo at Screening and BL visits. All participants who do not have the features of active vitiligo (defined below) will be classified as having stable disease.
Active vitiligo is defined as:
Participants will be classified as having active vitiligo based on the presence of at least one active lesion at BL defined as one of the following:
- New/extending lesions(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record);
- Confetti-like lesion(s); Confetti-like depigmentation is characterized by the presence of numerous 1-mm to 5-mm depigmented macules in clusters;
- Trichrome lesion(s); Trichrome lesions have a hypopigmented zone of varying width between normal and completely depigmented skin, resulting in 3 different hues of skin;
- Koebner phenomenon/phenomena (excluding Type 1 [history based on isomorphic reaction]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement.
Stable vitiligo is defined as:
• Participants will be classified as having stable vitiligo based on an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) will be classified as having stable disease.
Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA.
-
Additional inclusion criteria are:
- If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study.
- Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit.
Exclusion Criteria:
Medical Conditions:
-
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Any psychiatric condition including recent or active suicidal ideation or behavior that meets defined criteria.
-
Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin:
- Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criteria (including but not limited to segmental vitiligo and mixed vitiligo).
- Currently have active forms of other hypopigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation [melanoma and mycosis fungoides], post-inflammatory hypopigmentation, pityriasis alba [minor manifestation of atopic dermatitis], senile leukoderma [age-related depigmentation], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma, and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted.
- Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, but not limited to morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or BL Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.
- Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions or leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions.
- Have a superficial skin infection within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.
-
General Infection History:
- Have a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1.
- Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves.
- Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium tuberculosis.
-
Specific Viral Infection History:
- History (single episode) of disseminated HZ or disseminated herpes simplex or recurrent (more than one episode of) localized, dermatomal HZ.
- Infected with HBV or HCV: all participants will undergo screening for HBV and HBC for eligibility.
- Participants who are positive for HCVAb and HCV RNA will not be eligible for this study.
- Have a known immunodeficiency disorder (including positive serology for HIV at screening) or a first-degree relative with a hereditary immunodeficiency.
-
Other Medical Conditions:
- Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle requirements.
- History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/hypersensitivity to any component (including excipients) of the study intervention.
- Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered current, fluctuating, or progressive.
- Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
- Abnormal findings on the Screening chest imaging (eg, chest x-ray). Chest imaging may be performed up to 12 weeks prior to screening. Documentation of the official reading must be located and available in the source documentation.
- Long QT Syndrome, a family history of Long QT Syndrome, or a history of TdP.
- Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
- Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study.
Prior/Concomitant Therapy:
-
Have received any of the prohibited treatment regimens specified.
Prior/Concurrent Clinical Study Experience:
-
Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 [Baseline] or within 5 half-lives, whichever is longer.
Diagnostic Assessments:
Any of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat:
-
Renal impairment
-
Hepatic dysfunction
-
Other laboratory abnormalities
-
Standard 12-lead ECG that demonstrates clinically relevant abnormalities
Other Exclusion Criteria:
-
Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Arm 1- Ritlecitinib 100 milligrams (mg)
Randomized to Ritlecitinib 100 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status. |
100mg Capsule 50mg Capsule |
|
Eksperymentalny: Arm 2- Ritlecitinib 50mg
Randomized to Ritlecitinib 50 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status. |
100mg Capsule 50mg Capsule |
|
Komparator placebo: Arm 3- Placebo
Randomized to Placebo QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status. |
Matching capsule |
|
Eksperymentalny: Arm 4- Ritlecitinib 100mg
Non-randomized open-label Ritlecitinib 100mg QD for 52 weeks. |
100mg Capsule 50mg Capsule |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Występowanie klinicznie istotnych nieprawidłowości w badaniach laboratoryjnych.
Ramy czasowe: Wartość wyjściowa przez 108 tygodni
|
Wartość wyjściowa przez 108 tygodni
|
|
|
US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52
Ramy czasowe: 52 Weeks
|
Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
52 Weeks
|
|
Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52
Ramy czasowe: 52 Weeks
|
Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline). |
52 Weeks
|
|
Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to discontinuation.
Ramy czasowe: Baseline through 108 weeks
|
To evaluate the safety and tolerability of ritlecitinib in adult participants with non segmental vitiligo |
Baseline through 108 weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Czas na ratowanie stosowania leków
Ramy czasowe: Wartość wyjściowa do 104. tygodnia
|
Wartość wyjściowa do 104. tygodnia
|
|
|
Response based on F-VASI75 at 24 and 36 weeks
Ramy czasowe: 24 and 36 Weeks
|
Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline. |
24 and 36 Weeks
|
|
US-Only: Response based on T-VASI50 at 24 and 36 weeks
Ramy czasowe: 24 and 36 weeks
|
Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline). |
24 and 36 weeks
|
|
Global (Other than US):Patient Global Impression of Severity-Face (PGIS-F)
Ramy czasowe: Week 24, 36 and week 52
|
To assess the effect of ritlecitinib compared to placebo on the PGIS-F at Week 24, 36 and 52 |
Week 24, 36 and week 52
|
|
Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Ramy czasowe: Week 24, 36 and week 52
|
To assess the effect of ritlecitinib compared to placebo on the PGIS-V at Week 24, 36 and 52 |
Week 24, 36 and week 52
|
|
Global (Other Than US): Response based on T-VASI50 at Week 24, 36 and 52
Ramy czasowe: Week 24, 36 and 52
|
Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline). |
Week 24, 36 and 52
|
|
Patient Global Impression of Change-Face (PGIC-F)
Ramy czasowe: Week 36 and week 52
|
To assess the effect of ritlecitinib compared to placebo on the PGIC-F at Weeks 36 and 52. |
Week 36 and week 52
|
|
Patient Global Impression of Change- Overall vitiligo(PGIC-V)
Ramy czasowe: Week 36 and week 52
|
To assess the effect of ritlecitinib compared to placebo on the PGIC-V at Weeks 36 and 52. |
Week 36 and week 52
|
|
Change from baseline in Dermatology Life Quality Index (DLQI)
Ramy czasowe: Week 52
|
To evaluate the change from baseline in DLQI at week 52 |
Week 52
|
|
Proportion of participants achieving disease stabilization
Ramy czasowe: Baseline through week 104
|
The difference in the proportion of participants with stable disease at all timepoints in participants with non segmental vitiligo treated with ritlecitinib 50 mg QD and 100mg compared to placebo |
Baseline through week 104
|
|
Response based on T-VASI50
Ramy czasowe: Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
|
Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
|
|
Response based on F-VASI75
Ramy czasowe: Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
|
Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) |
Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
|
|
Response based on T-VASI75
Ramy czasowe: Baseline through week 4, week 8, week 12, week 24, week 36, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
|
Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline) |
Baseline through week 4, week 8, week 12, week 24, week 36, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.
|
|
Global (Other than US): Response based on T-VASI75
Ramy czasowe: Baseline through week 52
|
Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline) |
Baseline through week 52
|
|
Proportion of participants with sustained improvement in T-VASI
Ramy czasowe: Week 36 through week 52
|
Defined as maintenance of ≥T-VASI50 from Week 36 to Week 52 |
Week 36 through week 52
|
|
Proportion of participants with sustained improvement in F-VASI
Ramy czasowe: Week 36 through week 52
|
Defined as maintenance of ≥F-VASI75 from Week 36 to 52 |
Week 36 through week 52
|
|
US-Only: Percentage change from baseline (% CFB) in F-VASI at Weeks 24, 36 and 52
Ramy czasowe: Weeks 24, 36 and 52
|
To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in F-VASI at Weeks 24, 36 and 52 |
Weeks 24, 36 and 52
|
|
US-Only: % CFB in T-VASI at weeks 24, 36 and 52
Ramy czasowe: Weeks 24, 36 and 52
|
To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in T-VASI at Weeks 24,36 and 52 |
Weeks 24, 36 and 52
|
|
Response based on T-VASI90
Ramy czasowe: Baseline through week 52
|
Proportion of participants achieving T-VASI90 (defined as at least 90% improvement in T-VASI from Baseline) |
Baseline through week 52
|
|
Response based on T-VASI100
Ramy czasowe: Baseline through week 52
|
Proportion of participants achieving T-VASI90 (defined as at least 100% improvement in T-VASI from Baseline) |
Baseline through week 52
|
|
Response based on F-VASI50
Ramy czasowe: Baseline through week 104
|
Proportion of participants achieving F-VASI50 (defined as at least 50% improvement in F-VASI from Baseline). |
Baseline through week 104
|
|
Change from baseline in the Hospital Anxiety and Depression Scale (HADS)
Ramy czasowe: Week 52
|
To assess the effect of ritlecitinib compared to placebo on depression and anxiety subscales of the HADS at week 52 |
Week 52
|
|
The proportion of patients achieving absence of depression on HADS depression subscale
Ramy czasowe: Week 52
|
Response based on a 'normal' subscale score indicative of an absence of depression (in participants with baseline HADS subscale scores indicative of depression) |
Week 52
|
|
The proportion of patients achieving absence of anxiety on HADS anxiety subscale
Ramy czasowe: Week 52
|
Response based on a 'normal' subscale score indicative of an absence of anxiety (in participants with baseline HADS subscale scores indicative of anxiety) |
Week 52
|
|
US-Only: Patient Global Impression of Severity-Face (PGIS-F)
Ramy czasowe: Week 52
|
To assess the effect of ritlecitinib compared to placebo on the PGIS-F at 52 |
Week 52
|
|
US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Ramy czasowe: Week 52
|
To assess the effect of ritlecitinib compared to placebo on the PGIS-V at 52 |
Week 52
|
|
% CFB in F-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.
Ramy czasowe: Baseline through week 104
|
To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in F-VASI at all time points |
Baseline through week 104
|
|
% CFB in T-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.
Ramy czasowe: Baseline through week 104
|
To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in T-VASI at all time points |
Baseline through week 104
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Pfizer CT.gov Call Center, Pfizer
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- B7981080
- 2022-502518-98-00 (Identyfikator rejestru: CTIS (EU))
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .